Home >> Top News >> Precision medicine conference to take place Sept. 12–13

Precision medicine conference to take place Sept. 12–13

Print Friendly, PDF & Email

Aug. 21, 2018—Precision medicine strategies and successes in improving patient outcomes are key themes when hospital and health network CEOs and administrators gather in Nashville Sept. 12–13 to hear from innovators at Vanderbilt University Medical Center, Geisinger Health, Northwell Health, Moffitt Cancer Center, and Seattle Children’s Hospital, among others.

“Precision Medicine for Hospital CEOs: What You Need to Know about Genetic Testing, Precision Medicine, and Population Health Management” (https://www.precisionmedicineforhospitals.com) will feature first-mover and early-adopter health networks sharing the strategies of their precision medicine programs and the patient care successes and outcomes.

Keynote speaker is Jeffery Balser, MD, PhD, CEO of Vanderbilt University Medical Center, which is internationally recognized for its pioneering efforts to bring precision medicine into daily clinical care. Attendees will gain insight into the early successes of precision medicine at Vanderbilt and learn how the health care big data base at Vanderbilt is being used to inform population health initiatives while also guiding the care clinicians provide daily.

Twenty speakers will share their experiences at bringing precision medicine, genetic medicine, and genetic testing into the daily care provided to patients.

For more information and to register, go to https://www.precisionmedicineforhospitals.com. Or contact Chris Garcia at 512-264-7103.


Check Also

Molecular ‘bucket list’ for renal cancer

September 2018—Leo Tolstoy is not listed as a coauthor on the most recent iteration of The Cancer Genome Atlas on renal cell carcinoma, which focuses on molecular characterization of RCC. But the topic is as rich and complex as a Russian novel, and the authors’ approach is so comprehensive, it’s tempting to picture them at least holding forth at a certain soirée in Saint Petersburg (minus the after-party drunkenness and the bit with a bear, of course). The project may not be as sprawling as War and Peace, which marches 559 characters, speaking two languages, over four volumes, 15 parts, and 333 chapters. It’s a heroic effort nonetheless. There is much to keep track of in renal cell carcinoma, both generally and in this latest document, which evaluates 843 RCCs from three major histologic subtypes, including 488 clear cell RCC, 274 papillary RCC, and 81 chromophobe RCC.